Table 2.
Demographics and clinical features of COVID-19 mimicker group
| Literature cases (n = 4) | Our cases (n = 3) | Total (n = 7) |
|
|---|---|---|---|
| Age, median (min–max) | 35 (20–41) | 46 (30–61) | 40 (20–61) |
| Male, n (%) | 1 (25) | 1 (33.3) | 2 (28.5) |
| EGPA features, n (%) | |||
| Asthma | 3 (75) | 3 (100) | 6 (85.7) |
| Eosinophilia | 4 (100) | 2 (66.6) | 6 (85.7) |
| Coronary vasculitis | 1(25) | 2 (66.6) | 3 (42.8) |
| Allergic rhinitis | 0 | 2 (66.6) | 2 (28,5) |
| Hematuria | 1 (25) | 1 (33.3) | 2 (28,5) |
| Nasal polyps | 1 (25) | 0 | 1 (14.2) |
| MPO-ANCA positivity | 1 (25) | 0 | 1 (14.2) |
| Cutaneous lesions | 1 (25) | 0 | 1 (14.2) |
| Drop-foot | 1 (25) | 0 | 1 (14.2) |
| PR3-ANCA positivity | 0 | 0 | 0 (0) |
| Proteinuria | 0 | 0 | 0 (0) |
| Elevated serum creatinine | 0 | 0 | 0 (0) |
| Comorbidities, n (%) | |||
| Diabetes mellitus | 0 | 1 (33.3) | 1 (14.2) |
| Hypertension | 0 | 1 (33.3) | 1 (14.2) |
| Symptoms on admission, n (%) | |||
| Dyspnea | 3 (75) | 3 (100) | 6 (85.7) |
| Cough | 2 (50) | 3 (100) | 5 (71.4) |
| Malaise | 0 | 2 (66.6) | 2 (28,5) |
| Chest pain | 1 (25) | 1 (33.3) | 2 (28,5) |
| Fever | 1 (25) | 0 | 1 (14.2) |
| Myalgia | 0 | 1 (33.3) | 1 (14.2) |
| Nausea | 0 | 1 (33.3) | 1 (14.2) |
| Vomiting | 0 | 1 (33.3) | 1 (14.2) |
| Positive COVID-19 PCR test, n (%) | 0 | 0 | 0 |
| Eosinophilia, n (%) | 4 (100) | 2 (66.6) | 6 (85.7) |
| Lymphopenia, n (%)a | – | 0 | 0 |
| Ground-glass opacities in thorax CT, n (%) | 4 (100) | 3 (100) | 7 (100) |
| Elevated CRP (> 5 mg/l), n (%) | 3 (75) | 3 (100) | 6 (85.7) |
| Need for oxygen support, n (%) | 2 (50) | 2 (66.6) | 4 (57.1) |
| Mortality, n (%) | 0 | 1 (33.3) | 1 (14.2) |
COVID-19 coronavirus disease 2019, n number, min minimum, max maximum, EGPA eosinophilic granulomatosis with polyangitis, PCR polymerized chain reaction, CT computed tomography, CRP c-reactive protein
aliterature cases were missing lymphocyte count